151 related articles for article (PubMed ID: 26180381)
1. A novel approach for lung delivery of rifampicin-loaded liposomes in dry powder form for the treatment of tuberculosis.
Patil JS; Devi VK; Devi K; Sarasija S
Lung India; 2015; 32(4):331-8. PubMed ID: 26180381
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of rifampicin after repeated intra-tracheal administration of amorphous and crystalline powder formulations to Sprague Dawley rats.
Khadka P; Sinha S; Tucker IG; Dummer J; Hill PC; Katare R; Das SC
Eur J Pharm Biopharm; 2021 May; 162():1-11. PubMed ID: 33639255
[TBL] [Abstract][Full Text] [Related]
3. Rifampicin loaded chitosan nanoparticle dry powder presents an improved therapeutic approach for alveolar tuberculosis.
Rawal T; Parmar R; Tyagi RK; Butani S
Colloids Surf B Biointerfaces; 2017 Jun; 154():321-330. PubMed ID: 28363192
[TBL] [Abstract][Full Text] [Related]
4. Dry-Powder Inhaler Formulation of Rifampicin: An Improved Targeted Delivery System for Alveolar Tuberculosis.
Rawal T; Kremer L; Halloum I; Butani S
J Aerosol Med Pulm Drug Deliv; 2017 Dec; 30(6):388-398. PubMed ID: 28510480
[TBL] [Abstract][Full Text] [Related]
5. Rifampicin-loaded liposomes for the passive targeting to alveolar macrophages: in vitro and in vivo evaluation.
Zaru M; Sinico C; De Logu A; Caddeo C; Lai F; Manca ML; Fadda AM
J Liposome Res; 2009; 19(1):68-76. PubMed ID: 19515009
[TBL] [Abstract][Full Text] [Related]
6. Development and Evaluation of Chitosan Microparticles Based Dry Powder Inhalation Formulations of Rifampicin and Rifabutin.
Pai RV; Jain RR; Bannalikar AS; Menon MD
J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):179-95. PubMed ID: 26406162
[TBL] [Abstract][Full Text] [Related]
7. Liposomes for drug delivery to the lungs by nebulization.
Zaru M; Mourtas S; Klepetsanis P; Fadda AM; Antimisiaris SG
Eur J Pharm Biopharm; 2007 Nov; 67(3):655-66. PubMed ID: 17540552
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in liposomal dry powder formulations: preparation and evaluation.
Misra A; Jinturkar K; Patel D; Lalani J; Chougule M
Expert Opin Drug Deliv; 2009 Jan; 6(1):71-89. PubMed ID: 19236209
[TBL] [Abstract][Full Text] [Related]
9. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.
Pandey R; Sharma A; Zahoor A; Sharma S; Khuller GK; Prasad B
J Antimicrob Chemother; 2003 Dec; 52(6):981-6. PubMed ID: 14613962
[TBL] [Abstract][Full Text] [Related]
10. Spray-freeze-dried dry powder inhalation of insulin-loaded liposomes for enhanced pulmonary delivery.
Bi R; Shao W; Wang Q; Zhang N
J Drug Target; 2008 Nov; 16(9):639-48. PubMed ID: 18982512
[TBL] [Abstract][Full Text] [Related]
11. Formulation of rifampicin-cyclodextrin complexes for lung nebulization.
Tewes F; Brillault J; Couet W; Olivier JC
J Control Release; 2008 Jul; 129(2):93-9. PubMed ID: 18514353
[TBL] [Abstract][Full Text] [Related]
12. Effects of the antibiotic component on in-vitro bacterial killing, physico-chemical properties, aerosolization and dissolution of a ternary-combinational inhalation powder formulation of antibiotics for pan-drug resistant Gram-negative lung infections.
Mangal S; Huang J; Shetty N; Park H; Lin YW; Yu HH; Zemlyanov D; Velkov T; Li J; Zhou QT
Int J Pharm; 2019 Apr; 561():102-113. PubMed ID: 30797863
[TBL] [Abstract][Full Text] [Related]
13. Nebulization of Cyclic Arginine-Glycine-(D)-Aspartic Acid-Peptide Grafted and Drug Encapsulated Liposomes for Inhibition of Acute Lung Injury.
Desu HR; Thoma LA; Wood GC
Pharm Res; 2018 Mar; 35(5):94. PubMed ID: 29536186
[TBL] [Abstract][Full Text] [Related]
14. Physicochemical characterization and stability of rifampicin liposome dry powder formulations for inhalation.
Changsan N; Chan HK; Separovic F; Srichana T
J Pharm Sci; 2009 Feb; 98(2):628-39. PubMed ID: 18484099
[TBL] [Abstract][Full Text] [Related]
15. Monitoring safety of liposomes containing rifampicin on respiratory cell lines and in vitro efficacy against Mycobacterium bovis in alveolar macrophages.
Changsan N; Nilkaeo A; Pungrassami P; Srichana T
J Drug Target; 2009 Dec; 17(10):751-62. PubMed ID: 19863196
[TBL] [Abstract][Full Text] [Related]
16. Development and Characterization of Nanoembedded Microparticles for Pulmonary Delivery of Antitubercular Drugs against Experimental Tuberculosis.
Goyal AK; Garg T; Rath G; Gupta UD; Gupta P
Mol Pharm; 2015 Nov; 12(11):3839-50. PubMed ID: 26436948
[TBL] [Abstract][Full Text] [Related]
17. Inhalable liposomes of Glycyrrhiza glabra extract for use in tuberculosis: formulation, in vitro characterization, in vivo lung deposition, and in vivo pharmacodynamic studies.
Viswanathan V; Pharande R; Bannalikar A; Gupta P; Gupta U; Mukne A
Drug Dev Ind Pharm; 2019 Jan; 45(1):11-20. PubMed ID: 30122088
[TBL] [Abstract][Full Text] [Related]
18. Prolonged release biodegradable vesicular carriers for rifampicin--formulation and kinetics of release.
Kamath MP; Shenoy BD; Tiwari SB; Karki R; Udupa N; Kotian M
Indian J Exp Biol; 2000 Feb; 38(2):113-8. PubMed ID: 11218826
[TBL] [Abstract][Full Text] [Related]
19. Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages.
Vyas SP; Kannan ME; Jain S; Mishra V; Singh P
Int J Pharm; 2004 Jan; 269(1):37-49. PubMed ID: 14698575
[TBL] [Abstract][Full Text] [Related]
20. Flurbiprofen-loaded ethanolic liposome particles for biomedical applications.
Paliwal S; Tilak A; Sharma J; Dave V; Sharma S; Verma K; Tak K; Reddy KR; Sadhu V
J Microbiol Methods; 2019 Jun; 161():18-27. PubMed ID: 30951793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
